Table 3.

Summary of ongoing clinical trials that obtain tumor tissue for analysis as part of their protocols

Study	Phase Number	Number of Patients	Recruitment Status	Pathology	Drug	Dose	Schedule Prior to Surgery	Specimens	Physiologic Effect
NCT01849146	Phase I	36	Recruiting	Recurrent glioblastoma	Adavosertib	Not specified	Not specified	Tumor, blood	pRb expression, Ki67, pCDC2, cleaved caspase 3
NCT01986348	Phase II	110	Active, not recruiting	Recurrent gliomas	Selinexor	60 mg twice per week	3 doses prior to surgery	Tumor, blood
NCT02101905	Pilot	33	Active, not recruiting	Recurrent high- grade glioma, EGFR amplified	Lapatinib	MTD	Days −2, and 0, last dose 3 h prior to surgery	Tumor	Total and phospho- EGFR, Ki67
NCT02133183	Phase I	40	Active, not recruiting	Recurrent glioblastoma	Sapanisertib	MTD	Not specified	Enhancing and non- enhancing tumor	IHC for pS6, p4EBP, pmTOR, and AKTpSer473; pharmacokinetics in enhancing tumor
NCT02337686	Phase II	18	Active, not recruiting	Recurrent glioblastoma	Pembrolizumab	200 mg i.v.	2 doses q3weeks	Tumor, blood	Polyfunctional effector T cells:Treg ratio
NCT02525692	Phase II	76	Recruiting	Recurrent glioblastoma ± H3 K27M mutation	ONC201	Not specified	Not specified	Tumor	Not specified
NCT02630030	Phase 0	3	Completed	Recurrent or progressive glioblastoma	Ixazomib	Not specified	Oral dose 3 h prior to surgery	Tumor	Pharmacokinetics in tumor tissue
NCT02850744	Phase II	10	Terminated	Recurrent glioblastoma	PQR309	80 mg	For 3 consecutive days prior to surgery	Tumor, CSF, skin	Pharmacokinetics in cerebrospinal fluid
NCT02852655	Pilot	35	Active, not recruiting	Glioblastoma	Pembrolizumab			Tumor, blood	Tumor infiltrating T-lymphocyte density
NCT02933736	Early phase I	48	Unknown	Meningioma	Ribociclib	900 mg/d	5 doses then 3 cohorts: 2–4, 4–8, 22–26 h after admin	Enhancing and non- enhancing tumor, CSF	Glioblastoma cohort published35
NCT02981940	Phase II	36	Active, not recruiting	Recurrent glioblastoma	Abemaciclib	b.i.d.	Short preoperative course	Enhancing tumor	pRB expression level
NCT03122197	Phase 0/I	42	Recruiting	Recurrent gliomas	Letrozole	2–12 mg/d	1–5 days preop and continuing postop	Enhancing tumor	Area under the curve in tumor tissue
NCT03027388	Phase II	20	Recruiting	Recurrent gliomas	LBIOO	2.33 mg/m2	1–12 h prior to surgery	Tumor tissues	Pharmacokinetics parameters in tumor tissues
NCT03107780	Phase 0/I	86	Recruiting	Recurrent glioblastoma	AMG-232	Dose escalation	2 doses prior to surgery (q.d. dosing)	Enhancing and nonenhancing tumor	Pharmacokinetics parameters in tumor tissue